COVID-19: Oxford’s vaccine trials to continue after a subject’s death
Category: #health  | By Nikita Chaurasia  | Date: 2020-10-23 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

COVID-19: Oxford’s vaccine trials to continue after a subject’s death
  • The deceased volunteer was reportedly subjected to a placebo and not the actual COVID-19 vaccine.
  • The Brazilian government plans on purchasing the patent COVID-19 vaccine if approved.

According to reliable sources, the demise of a volunteer occurred during AstraZeneca’s and Oxford’s COVID-19 trials, currently being conducted in Brazil. Following the review of the of the unfortunate event, health surveillance authority Anvisa (Agência Nacional de Vigilância Sanitária) has reportedly authorized the study to proceed without any disruptions.

The deceased volunteer was subjected to a placebo and not the actual COVID-19 vaccine, sources confirmed. In fact, the effectuality of the potential vaccine was evaluated on only half of the volunteers participating in the trial.

In this context, AstraZeneca issued a statement claiming that all the medical events are carefully monitored by trial investigators along with an independent safety monitoring committee. Providing assurance regarding the authenticity of the trials, the company further stated that it had followed all the prerequisite review processes.

According to the University of Oxford, all significant medical incidents, including those concerning the participants in the control group or the COVID-19 vaccine group, are reviewed independently.

It is to be noted that AstraZeneca conducted its phase 1 and 2 trials for the potential vaccine candidate, while the phase 3 trial is currently being carried out in India, Brazil, and in the United Kingdom.

Reportedly, the Brazilian regulator has suggested that the companies to continue their trial round. Moreover, the Brazilian government plans on purchasing the patent COVID-19 vaccine if it is approved by the regulatory bodies.

Meanwhile, Brazil’s President Jair Bolsonaro has reportedly declared that the federal government will not buy a COVID-19 vaccine from China-based biopharmaceutical company Sinovac Biotech Ltd.

 

Source credits: https://www.bbc.com/news/world-latin-america-54634518

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Goldman Sachs provides unlimited holidays to its senior employees

Goldman Sachs provides unlimited holidays to its senior employees

By Nikita Chaurasia

Goldman Sachs has recently announced a flexible vacation scheme under which the company’s senior employees can take unlimited paid leaves annually. As per sources, the global investment bank has unveiled a new policy that will allow senior sta...

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...